<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To determine the prevalence and characteristics of <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> in <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) patients with persistent symptoms who are non-responsive to medical therapy </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Sixty-five patients (40 male, 25 female; mean age, 50 +/- 7.8 years) who continued to report symptoms after 8 wk of high-dose <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> (<z:chebi fb="4" ids="53266">PPI</z:chebi>) therapy, as well as 18 patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, were studied </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients filled out symptom questionnaires and underwent endoscopy, manometry and combined pH-metry and bilimetry </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: There were 4 groups of patients: 22 (26.5%) without <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, 24 (28.9%) grade A-B <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, 19 (22.8%) grade C-D and 18 (21.6%) <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Heartburn was present in 71 patients (85.5%) and regurgitation in 55 (66.2%), with 44 (53%) reporting simultaneous heartburn and regurgitation </plain></SENT>
<SENT sid="5" pm="."><plain>The prevalence of pathologic <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> in the groups without <z:hpo ids='HP_0100633'>esophagitis</z:hpo> and with grades A-B and C-D <z:hpo ids='HP_0100633'>esophagitis</z:hpo> was 45.4%, 66.6% and 73.6%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The prevalence of pathologic <z:chebi fb="0" ids="16990">bilirubin</z:chebi> exposure in these 3 groups was 53.3%, 75% and 78.9%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The overall prevalence of <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> in non-responsive patients was 68.7% </plain></SENT>
<SENT sid="8" pm="."><plain>Pathologic acid and <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e> was observed in 22.7% and 58.1% of non-esophagitic patients and esophagitic patients, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The high percentage of patients poorly responsive to <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy may result from poor control of duodenogastroesophageal reflux </plain></SENT>
<SENT sid="10" pm="."><plain>Many patients without <z:hpo ids='HP_0100633'>esophagitis</z:hpo> have simultaneous acid and <z:e sem="disease" ids="C0005403" disease_type="Disease or Syndrome" abbrv="">bile reflux</z:e>, which increases with increasing <z:hpo ids='HP_0100633'>esophagitis</z:hpo> grade </plain></SENT>
</text></document>